#Vienna #Austria #RNA Sequencing #Lexogen #Ochre Bio

Lexogen's Remarkable Achievement in Human Cell Sequencing

Lexogen, a renowned biotechnology firm based in Vienna, has made significant strides in RNA sequencing technology, announcing the successful completion of a large-scale project in partnership with Ochre Bio. This groundbreaking endeavor involved generating extensive genomic datasets from human primary hepatocytes, a key aspect in the study of liver diseases. By processing over 120,000 samples, Lexogen utilized its proprietary non-extraction RNA sequencing platform, showcasing its advanced capabilities in high-resolution gene expression profiling and next-generation sequencing (NGS) services.

Ochre Bio's mission focuses on developing RNA-based medicines aimed at chronic liver diseases that remain inadequately treated. The company integrates a wide array of human liver data, maintaining a comprehensive atlas of genetic disruptions and ailments to facilitate the identification of therapeutic targets and causal pathways. Ochre Bio's OBELiX software plays a crucial role in this process, enabling researchers to investigate genetic biology within human cells and tissues, while leveraging an AI-driven discovery engine to prioritize disease-related targets.

The accuracy and fidelity of RNA sequencing data prove vital for Ochre's human discovery platform. For several years, Lexogen has been a trusted partner, consistently providing high-quality RNA-seq data derived from various sample types, including formalin-fixed paraffin-embedded (FFPE) specimens, microbial samples, and primary hepatocytes. Operating in compliance with current Good Laboratory Practices (cGLP), Lexogen's NGS Services employ proprietary technologies designed and manufactured under ISO 13485 standards in Vienna, Austria. Their expert teams offer cutting-edge workflows that are both optimized and customizable, ensuring the best outcomes across diverse and complex samples.

Lexogen's patented technologies, including THOR and pooling methods, facilitate high-throughput RNA sequencing with exceptional consistency and resolution. Quin Wills, founder and CEO of Ochre Bio, emphasized the import of data quality in AI-based target discovery, praising the outstanding performance and reproducibility of Lexogen's services. He explained: "The power of a platform relies on the quality of the data it rests upon. With over 120,000 samples from primary human hepatocytes, consistent data quality is essential for interpreting results accurately. Our collaboration with Lexogen has led to high-fidelity sequencing data, allowing machine learning models to effectively differentiate biological signals from technical noise."

Stephane Barges, CEO of Lexogen, expressed a strong commitment to delivering high-quality services on a large scale, stating: "Providing reliable and accurate data is crucial to our work, and we adhere to the highest standards at every stage of the process. We strive to support our partners in advancing their discoveries and accelerating innovation. Our mission is to contribute positively to patient care through the development of therapies and diagnostic tools."

For nearly two decades, Lexogen has delivered an array of solutions for transcriptomic analysis and RNA sequencing, including kits, reagents, bioinformatics, and contract research organization (CRO) services. All products are designed and manufactured in Vienna, while sequencing services are provided from the same location, ensuring a robust quality framework. Lexogen is committed to regulatory compliance, maintaining ISO 9001 and 13485 certifications, and ensuring all services comply with current Good Laboratory Practices (cGLP) and GDPR regulations.

For more information about Lexogen and their innovative solutions, visit their website at www.lexogen.com and follow them on Twitter @lexogen.